| Source: |
| Type: |
| Synergy — Interaction in which two or more agents, treatments, or biological interventions produce a combined effect greater than would be expected from their individual effects. In pharmacology and cancer research, synergy commonly refers to enhanced therapeutic efficacy when a compound is combined with chemotherapy, radiation, targeted therapy, or another bioactive agent. Typical modulation in cancer: ↑ synergy is generally favorable when it increases tumor-cell killing, suppresses proliferation, enhances apoptosis or ferroptosis, or improves sensitivity to anticancer therapy. Synergy should be distinguished from simple additive effects and ideally supported by quantitative combination analysis such as combination index, Bliss independence, Loewe additivity, or related methods. Typical modulation in Alzheimer’s disease: Context-dependent. Synergy may describe enhanced neuroprotective, anti-inflammatory, antioxidant, or cognitive effects produced by combinations of compounds or treatments, but it is not a disease-specific molecular pathway. |
| 9030- | Phyco, | Enhancing the gastrointestinal stability of phycocyanin through modified PEGylation: Prospects for oral anticancer treatment |
| - | in-vitro, | Oral, | NA |
| 3587- | PI, | Piperine: A review of its biological effects |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3595- | PI, | Black pepper and health claims: a comprehensive treatise |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2943- | PL, | Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF7 |
| 2951- | PL, | AF, | Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells |
| - | in-vitro, | GBM, | U87MG |
| 1941- | PL, | Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer |
| - | in-vitro, | HNSCC, | NA |
| 1948- | PL, | BNL, | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
| - | in-vitro, | GBM, | NA |
| 9113- | PRO, | Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers |
| - | Review, | Var, | NA |
| 3917- | PS, | Phosphatidylserine, inflammation, and central nervous system diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4965- | PSO, | Cisplatin, | The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis |
| - | vitro+vivo, | GC, | HGC27 | - | vitro+vivo, | GC, | MKN45 |
| 1994- | PTL, | Parthenolide Inhibits Tumor Cell Growth and Metastasis in Melanoma A2058 Cells |
| - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | Nor, | L929 |
| 4690- | PTS, | immuno, | Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies |
| - | Review, | Var, | NA |
| 3347- | QC, | Recent Advances in Potential Health Benefits of Quercetin |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3343- | QC, | Quercetin, a Flavonoid with Great Pharmacological Capacity |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Arthritis, | NA |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 3380- | QC, | Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases |
| - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3376- | QC, | Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 |
| 3607- | QC, | Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 39- | QC, | A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells |
| - | Analysis, | Var, | NA |
| 97- | QC, | HPT, | Effects of the flavonoid drug Quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo |
| - | in-vitro, | Pca, | PC3 |
| 94- | QC, | HPT, | Effects of quercetin on the heat-induced cytotoxicity of prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | JCA-1 |
| 81- | QC, | EGCG, | Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea |
| - | in-vivo, | Pca, | NA |
| 4827- | QC, | CUR, | Synthetic Pathways and the Therapeutic Potential of Quercetin and Curcumin |
| - | Review, | Var, | NA |
| 5030- | QC, | Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy |
| - | in-vivo, | Nor, | NA |
| 1391- | RES, | BBR, | Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells |
| - | in-vitro, | Tong, | SCC25 |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 3079- | RES, | Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action |
| - | Review, | Var, | NA |
| 3087- | RES, | Resveratrol cytotoxicity is energy-dependent |
| - | Review, | Var, | NA |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF7 |
| 2991- | RES, | Chemo, | Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells |
| - | in-vitro, | Melanoma, | MSTO-211H | - | in-vitro, | Nor, | MeT5A |
| 1747- | RosA, | Molecular Pathways of Rosmarinic Acid Anticancer Activity in Triple-Negative Breast Cancer Cells: A Literature Review |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MDA-MB-468 |
| 1742- | RosA, | Rosmarinic acid, a natural polyphenol, has a potential pro-oxidant risk via NADH-mediated oxidative DNA damage |
| - | Analysis, | Var, | NA |
| 1744- | RosA, | Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity |
| - | Review, | Var, | NA |
| 3007- | RosA, | Hepatoprotective effects of rosmarinic acid: Insight into its mechanisms of action |
| - | Review, | Nor, | NA |
| 3002- | RosA, | Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols |
| - | Review, | Var, | NA |
| 4904- | Sal, | CUR, | Co-delivery of Salinomycin and Curcumin for Cancer Stem Cell Treatment by Inhibition of Cell Proliferation, Cell Cycle Arrest, and Epithelial–Mesenchymal Transition |
| - | in-vitro, | Var, | NA |
| 4906- | Sal, | A Concise Review of Prodigious Salinomycin and Its Derivatives Effective in Treatment of Breast Cancer: (2012–2022) |
| - | Review, | BC, | NA |
| 5036- | SAS, | Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 4603- | SeNPs, | Therapeutic applications of selenium nanoparticles |
| - | Review, | Var, | NA |
| 4612- | SeNPs, | Rad, | Histopathological Evaluation of Radioprotective Effects: Selenium Nanoparticles Protect Lung Tissue from Radiation Damage |
| - | in-vivo, | Nor, | NA |
| 4608- | SeNPs, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 9278- | SES, SSM, | Antitumor Effects of Sesamin via the LincRNA-p21/STAT3 Axis in Human Bladder Cancer: Inhibition of Metastatic Progression and Enhanced Chemosensitivity |
| - | vitro+vivo, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 3198- | SFN, | Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells |
| - | in-vitro, | Pca, | NA |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
| 1465- | SFN, | TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells |
| - | in-vitro, | Bladder, | NA |
| 1508- | SFN, | Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment |
| - | Review, | Var, | NA |
| 1478- | SFN, | acet, | Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells |
| - | in-vitro, | Nor, | NA |
| 1476- | SFN, | PDT, | Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane |
| - | in-vitro, | HNSCC, | NA |
| 1475- | SFN, | Form, | Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Cerv, | HeLa |
| - | in-vitro, | BrCC, | H720 | - | in-vivo, | BrCC, | NA | - | in-vitro, | BrCC, | H727 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1849 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid